{
    "Clinical Trial ID": "NCT00171314",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Upfront Zoledronic Acid",
        "  Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.",
        "INTERVENTION 2: ",
        "  Delayed Zoledronic Acid",
        "  Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Stage I-IIIa breast cancer",
        "  Postmenopausal",
        "  Recent surgery for breast cancer",
        "Exclusion Criteria:",
        "  Metastatic disease",
        "  Invasive bilateral disease",
        "  Clinical or radiological evidence of existing fracture in spine or hip",
        "  Other protocol-defined inclusion / exclusion criteria may apply."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy",
        "  Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = [(BMD at Visit - BMD at Baseline) / BMD at Baseline] * 100.",
        "  Time frame: From Baseline - 12 months",
        "Results 1: ",
        "  Arm/Group Title: Upfront Zoledronic Acid",
        "  Arm/Group Description: Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.",
        "  Overall Number of Participants Analyzed: 254",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Percent Change  2.680         (2.8451)",
        "Results 2: ",
        "  Arm/Group Title: Delayed Zoledronic Acid",
        "  Arm/Group Description: Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.",
        "  Overall Number of Participants Analyzed: 269",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Percent Change  -3.314         (3.9632)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 47/254 (18.50%)",
        "  Anaemia 1/254 (0.39%)",
        "  Febrile neutropenia 1/254 (0.39%)",
        "  Lymphadenopathy 1/254 (0.39%)",
        "  Acute myocardial infarction 1/254 (0.39%)",
        "  Angina pectoris 0/254 (0.00%)",
        "  Angina unstable 0/254 (0.00%)",
        "  Bundle branch block left 0/254 (0.00%)",
        "  Cardiac failure 4/254 (1.57%)",
        "  Coronary artery disease 0/254 (0.00%)",
        "  Coronary artery stenosis 1/254 (0.39%)",
        "Adverse Events 2:",
        "  Total: 56/269 (20.82%)",
        "  Anaemia 1/269 (0.37%)",
        "  Febrile neutropenia 0/269 (0.00%)",
        "  Lymphadenopathy 0/269 (0.00%)",
        "  Acute myocardial infarction 0/269 (0.00%)",
        "  Angina pectoris 3/269 (1.12%)",
        "  Angina unstable 1/269 (0.37%)",
        "  Bundle branch block left 1/269 (0.37%)",
        "  Cardiac failure 1/269 (0.37%)",
        "  Coronary artery disease 1/269 (0.37%)",
        "  Coronary artery stenosis 0/269 (0.00%)"
    ]
}